Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that the Company was informed today by Dr. Alastair Clemow, a director of the Company that he purchased 4,500 shares of common stock on the open market on December 16, 2013 at an average price of $5.7787 per share.

Following this purchase, Dr. Clemow now owns 18,500 shares of common stock, which represents approximately 0.1 per cent of the total issued shares of common stock. Dr. Clemow also has the right to purchase up to 105,714 shares of common stock pursuant to options previously granted (in aggregate Dr. Clemow’s shares of common stock and options represent 124,214 shares of common stock which represent approximately 0.7 per cent of the Company’s total issued shares of common stock).

This announcement is being made pursuant to the London Stock Exchange’s AIM Rules for Companies admitted to trading on the AIM market.

About Medgenics

Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others. For more information, please visit www.medgenics.com.

Medgenics, Inc.John Leaman, CFOjohn.leaman@medgenics.comorLHAAnne Marie Fields212-838-3777afields@lhai.com@LHA_IR_PRorAbchurch CommunicationsJoanne Shears / Jamie Hooper / Harriet Rae+44 207 398 7718harriet.rae@abchurch-group.comorOriel Securities (NOMAD & Broker)Jonathan Senior / Giles Balleny+44 207 710 7617

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Medgenics(Regs) Charts.